07 January 2019
binx health, a pioneer in convenient health, today announced that it has appointed Samar Parikh to its Board of Directors. Mr. Parikh has held various leadership positions within Amazon, including as an early catalyst behind its entry into healthcare. Parikh was also instrumental in the company's recent acquisition of PillPack. His roles at Amazon have included Global Leader, Business Development & Strategy (Consumables & Consumer Healthcare) and General Manager, CPG, Consumer Healthcare, and Consumer Healthcare Innovation, where he was responsible for managing Amazon's retail businesses across consumer-packaged goods, consumer healthcare and medical devices.
03 January 2019
Tragara Pharmaceuticals Inc. today announced the appointment of Scott Megaffin as Chief Executive Officer and a member of the Board of Directors effective immediately. Megaffin brings extensive leadership experience in clinical stage companies in oncology, specialty and critical care. He replaces Tom Estok, who will remain active with the company as an advisor and continue in his role on the Board of Directors.
19 December 2018
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that it has submitted a New Drug Application (“NDA”) for XIPERETM to the U.S. Food and Drug Administration (“FDA”) for the treatment of macular edema associated with uveitis.
18 December 2018
Patients wondering if they have the sexually transmitted infections ("STI") chlamydia or gonorrhea may soon be able to get the results in about 30 minutes, according to new research funded through the National Institutes of Health. The binx health (formerly Atlas Genetics) result could lead to immediate treatment and an associated reduction in the spread of the infection. The World Health Organization has identified chlamydia and gonorrhea, among the most prevalent STIs, as organisms without an available point-of-care (POC) test.
12 December 2018
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of $3.75 per share. The total public offering size is expected to be $45.0 million , before deducting the underwriting discounts and commissions and other offering expenses payable by the Company.
11 December 2018
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Marinus. Jefferies LLC and Leerink Partners LLC are acting as joint bookrunning managers for the offering. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock.
10 December 2018
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the Magnolia Study) and oral (the Amaryllis Study) in women with postpartum depression (PPD). Based on these results, the Company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens.
04 December 2018
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that ganaxolone data from its Phase 2 clinical trial in pediatric genetic epilepsies, CDKL5 Deficiency Disorder (CDD) and PCDH19-related pediatric epilepsy (PCDH19 epilepsy) were presented at the American Epilepsy Society ( AES ) Annual Meeting in New Orleans on December 2 and 3, 2018.
09 November 2018
Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today announced it will present positive data from its recently completed Phase IB/IIA trial of AT-527 in treatment-naïve HCV-infected patients, including HCV-infected patients with Child-Pugh A (CPA) cirrhosis. The data will be presented on November 10, 2018 at The Liver Meeting® 2018 sponsored by the American Association for the Study of Liver Diseases taking place in San Francisco, California.
08 November 2018
Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended September 30, 2018 and provided an update on its development programs.
20 March 2019
20 March 2019
20 March 2019
19 March 2019